Net Income (Loss) Per Share Attributable to Common Stockholders - Schedule of Earnings, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2026	Jun. 30, 2026	Mar. 31, 2026	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2026	Sep. 30, 2025
Numerator:
Net income (loss)	$ 60,110	$ (69,029)	$ (63,559)	$ (64,469)	$ (58,731)	$ (57,874)	$ (72,478)	$ (181,074)
Add: interest expense on convertible note	752			0
Net income (loss) – diluted	$ 60,862			$ (64,469)			$ (72,478)	$ (181,074)
Denominator:
Weighted-average shares of common stock outstanding - basic (in shares)	100,174,038			68,016,817			78,885,912	67,998,124
Dilutive effect of stock options, warrants and RSUs (in shares)	1,713,545			0			0	0
Dilutive effect of Roche convertible note (if-converted) (in shares)	1,334,258			0			0	0
Weighted-average shares of common stock outstanding - Diluted (in shares)	103,221,841			68,016,817			78,885,912	67,998,124
Net income (loss) per share attributable to common stockholders - basic (in dollars per share)	$ 0.60			$ (0.95)			$ (0.92)	$ (2.66)
Net income (loss) per share attributable to common stockholders - diluted (in dollars per share)	$ 0.58			$ (0.95)			$ (0.92)	$ (2.66)